Back to Agenda
Changing Global Regulatory Climates: Effects on Companion Diagnostics and Combination Products
Session Chair(s)
Shayesteh Fürst-Ladani, MBA, MS
CEO
SFL Regulatory Affairs & Scientific Communication, Switzerland
This session will focus on EU and US FDA developments in the regulation of drug/device combination products and companion diagnostics with an emphasis on clinical considerations. The session will provide an overview of the revision of the EU medtech legislation and summarize the main changes of the latest development of the proposed medical devices and in vitro diagnostic regulations. This will include an assessment on the impact of these changes on the regulatory framework for combination products and companion diagnostics. How these amendments will affect clinical study design of drugs and companion diagnostics will be highlighted. The session will also include discussion of FDA current and future guidance, including human factor considerations in developing combination products.
Learning Objective : Describe the latest update on the revision of EU medtech law and impact on regulatory processes for companion diagnostics and combination products; Discuss considerations for clinical studies for companion diagnostics and drugs; Provide an overview of current FDA technical guidance on specific product areas and guidance in development.
Speaker(s)
Revision of EU Medtech Law: Impact on Regulatory Framework of Companion Diagnostics and Combination Products
Shayesteh Fürst-Ladani, MBA, MS
SFL Regulatory Affairs & Scientific Communication, Switzerland
CEO
Global Clinical Trial Design Considerations When Incorporating a Companion Diagnostic
Sabah Malek
Eisai Inc., United States
Director, Regulatory Affairs, Oncology Business Group
US FDA Regulation of Combination Products: Clinical and Technical Considerations
Patricia Love, MD, MBA
FDA, United States
Deputy Director, Office of Combination Products, OCPP, OC
Have an account?